Correction to “The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids”

Abstract

Numata M, Kandasamy P, Voelker DR. The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids. Immunol Rev. 2023; 317: 166–186. doi:10.1111/imr.13207

In the article, the second paragraph was inadvertently added to Summary section and should have been removed.

The Summary reads:

The minor anionic pulmonary surfactant phospholipids, POPG and PI, exhibit anti-inflammatory effects as antagonists for multiple TLRs. These lipids also have strong efficacies as antivirals against multiple respiratory RNA-enveloped viruses such as RSV, IAVs, and SARS-CoV-2. PI also has a potent effect against non-enveloped virus (human rhinovirus A). These lipids also have very strong potential to be applied as anti-inflammatory compounds for acute lung injury, induced by cytokine storms, including severe COVID-19.

We determined the antiviral efficacy of POPG against five clinical isolates of RSV (designated by GenBank accession numbers) and recombinant strains of RSV (rA2-A2F, rA2-19F, and rA2 Long F) in comparison with RSV-A2.¹² The titer of each strain is shown as PFU/mL, and the efficacies of POPG and POPC (200 μg/mL) on each strain are stated as the viral titers by plaque assays. Data are shown as means ± SD from two independent experiments.

The Summary should read:

The minor anionic pulmonary surfactant phospholipids, POPG and PI, exhibit anti-inflammatory effects as antagonists for multiple TLRs. These lipids also have strong efficacies as antivirals against multiple respiratory RNA-enveloped viruses such as RSV, IAVs, and SARS-CoV-2. PI also has a potent effect against non-enveloped virus (human rhinovirus A). These lipids also have very strong potential to be applied as anti-inflammatory compounds for acute lung injury, induced by cytokine storms, including severe COVID-19.

We apologize for this error.